Amplyx announces data from phase 2 clinical trial of fosmanogepix
Category: #healthcare  By Mateen Dalal  Date: 2020-07-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Amplyx announces data from phase 2 clinical trial of fosmanogepix

Amplyx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing small molecules drugs, has reportedly announced the positive top-line outcomes from its Phase 2 clinical trial of fosmanogepix.

Sources cite that the company conducted this clinical trial to develop a first-line treatment for patients with invasive infections caused by Candida. The trial was open-label, multicenter, single-arm, a non-comparative study evaluating the safety and efficacy of fosmanogepix. All patients were treated with fosmanogepix for up to 14 days.

According to sources familiar with the knowledge of matter, the clinical trial met its primary endpoint, showing an 80% treatment success rate. The drug was well tolerated in patients and didn’t demonstrate any adverse events or discontinuations. Moreover, the drug showed potent in vitro activity against Candida isolates obtained from patients, together with isolates resistant to additional antifungal agents.

Meanwhile, the additional Phase 2 clinical trials are ongoing in patients with life-threating Aspergillus and rare mold infections, and infections caused due to drug-resistant Candida Auris. 

Michael R. Hodges, M.D., Chief Medical Officer at Amplyx said that the company is encouraged that fosmanogepix showed a high treatment success rate, including activity against resistant pathogens, and was tolerated pretty well in patients with invasive infections. Notably, patients were able to conveniently transition from intravenous to oral formulations during a clinical trial, he states.

Mr. Hodges added that the positive safety and efficacy data from the Phase 2 clinical trial highlights the effectiveness of fosmanogepix as a novel differentiated treatment option for patients who develop invasive fungal infections.

In 2019, the U.S. Centers for Disease Control (CDC) announced drug-resistant Candida Auris, other Candida strains, and Aspergillus as a threat to public health. This highlights the need for innovation in the antifungal landscape, particularly those with novel mechanisms of action. 

Source Credit - https://amplyx.com/amplyx-announces-positive-top-line-data-in-phase-2-clinical-trial-of-novel-antifungal-fosmanogepix/

 

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Tesla’s highly awaited cybertruck to face production delays until 2022
Tesla’s highly awaited cybertruck to face production delays until 2022
By Mateen Dalal

This EV pickup truck has an unorthodox design and boasts a formidable range of over 400 kms. The ...

French lawmakers approve a bill to deal with fourth wave of Coronavirus
French lawmakers approve a bill to deal with fourth wave of Coronavirus
By Mateen Dalal

The French parliament recently approved a bill that makes Covid-19 vaccination mandatory for health ...

China scraps WHO’s plans for 2nd phase of Covid-19 origin study
China scraps WHO’s plans for 2nd phase of Covid-19 origin study
By Mateen Dalal

The World Health Organization’s plan for a deeper probe into the origin of the coronavirus was...